stockrow
Saturday 7 November 2026
Export OCGN’s income statement to Excel — free account
Ocugen, Inc.
OCGN Healthcare Biotechnology
Ocugen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.4 million, up 8.83% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +84.9%
- Free cash flow
- −22.2%
- Total debt
- −93.7%
Quarter to September 2026, against a year earlier
0.93
0.11
+13.41%
Follow OCGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 2 | 2 |
+8 more TTM periods Free account |
| 923.92% | 1,211.66% | (660.00%) | (776.89%) | ||
| (78.91%) | (92.03%) | (118.11%) | (107.73%) | ||
ROIC |
0.00% | 0.00% | (1,317.07%) | 0.00% | |
Return on Tangible Assets |
442.71% | 628.74% | (226.29%) | (432.44%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.19) | (0.18) | (0.18) | (0.19) | |
Free Cash Flow |
(63.90) | (61.02) | (59.58) | (57.15) | |
Capital Expenditures |
(0.21) | (0.15) | (0.17) | (0.18) | |
| Other line items | |||||
Cash ROIC |
(93.49%) | (71.59%) | (89.11%) | (162.37%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
944.03% | 955.55% | 928.91% | 900.75% | |
Selling, General and Administrative Expense of Revenue |
600.44% | 648.89% | 654.94% | 624.95% | |
Share Based Compensation of Revenue |
192.26% | 201.05% | 206.49% | 174.64% | |
Interest Coverage |
(6.76) | (8.16) | (12.62) | (12.13) | |
Operating CF/Net income |
0.97 | 0.74 | 0.83 | 0.84 | |
Depreciation/Fixed assets |
0.45 | 0.40 | 0.28 | 0.26 | |
Capex/Depreciation |
(0.04) | (0.03) | (0.05) | (0.05) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.19) | (0.18) | (0.18) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.04 |
Columns are period end dates · fundamentals updated 6 Nov 2026